Modern Gastric Cancer Care: From Diagnosis to Treatment
Trastuzumab is used for the treatment of patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma.
The article reviews advances in diagnosis and treatment of gastric cancer, emphasizing the role of endoscopy, biopsy, imaging, staging, and the increasing importance of biomarker testing (HER2, PD‑L1, mismatch repair/MSI, CLDN18.2). It discusses targeted therapies such as trastuzumab for HER2‑positive disease and zolbetuximab for CLDN18.2‑positive disease, as well as immunotherapies like immune check‑point inhibitors, and describes how treatment plans are individualized based on tumor biology, stage, and patient factors.
The statement identifies a specific targeted therapy that has transformed the management of a subset of gastric cancer patients, highlighting the importance of biomarker status in guiding effective, personalized treatment.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Precision medicine in gastric cancer
- Gastric cancer
- DESTINY‑Gastric05 Phase 3 Trial of ENHERTU Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
- Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
- Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers